10-K: Prime Medicine Faces Going Concern Doubt Amidst Losses, Key Pipeline Shifts

Prime Medicine reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing its gene editing pipeline and securing new collaborations.

Summary

• Prime Medicine incurred a net loss of $201.1 million for the year ended December 31, 2025, increasing from $195.9 million in 2024, with an accumulated deficit of $888.4 million.
• The company's existing cash, cash equivalents, and investments of $177.7 million (excluding restricted cash) are projected to fund operations only into 2027, raising substantial doubt about its ability to continue as a going concern.
• Research and development expenses increased by $5.3 million to $160.6 million in 2025, primarily due to facility expansion and increased license/IP costs, partially offset by workforce reductions and deprioritization of certain programs.
• General and administrative expenses increased by $2.2 million to $52.3 million in 2025, driven by higher corporate legal expenses, partially offset by decreased personnel expenses.
• The PM359 program for Chronic Granulomatous Disease (CGD) showed positive Phase 1/2 clinical data, demonstrating restoration of functional protein activity, but was strategically deprioritized in May 2025.
• Lead programs PM577 for Wilson Disease and PM647 for Alpha-1 Antitrypsin Deficiency (AATD) are in late preclinical development, with IND/CTA submissions planned for 1H 2026 and mid-2026, respectively.
• A research collaboration and license agreement with Bristol-Myers Squibb (BMS) in September 2024 provided a $55.0 million upfront payment and a $55.0 million equity investment, with potential for over $3.5 billion in milestones and royalties.
• The Cystic Fibrosis Foundation (CFF) provided up to $15.0 million in 2024 and an additional $24.0 million in 2025 to support the development of Prime Editors for CF, including a $6.0 million cash funding and $6.0 million equity investment in 2025.
• Prime Medicine is engaged in arbitration proceedings with Beam Therapeutics regarding its AATD program, with Beam alleging breach of the collaboration agreement and seeking monetary damages or transfer of the program.
• The company holds 10 in-licensed U.S. patents/allowed applications and 20 ex-U.S. patents/allowed applications covering Prime Editing methods and components, but does not currently own any issued patents covering its core technology.
• Allan Reine, M.D., was appointed Chief Executive Officer in May 2025, succeeding Keith Gottesdiener, M.D., and Jeffrey Marrazzo became Executive Chair of the board.
• The company completed a public offering in August 2025, raising approximately $138.4 million in net proceeds from the sale of 43,700,000 shares of common stock.
• An at-the-market (ATM) equity offering program for up to $300.0 million was established in November 2023, with no shares sold under it as of December 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with significant caution due to the explicit 'going concern' warning, increasing net losses, and substantial cash burn, despite positive preclinical data and strategic collaborations. The legal dispute with Beam and reliance on in-licensed IP add further uncertainty.

Positives

• Positive early clinical data from the PM359 program for CGD demonstrated rapid and durable restoration of NADPH oxidase activity and no serious adverse events attributable to Prime Editing.
• Secured a significant research collaboration and license agreement with BMS, including a $55.0 million upfront payment, a $55.0 million equity investment, and potential milestones exceeding $3.5 billion.
• Received additional funding of up to $24.0 million from the Cystic Fibrosis Foundation in 2025 to accelerate CF program development, building on previous funding.
• Advancing a pipeline of wholly-owned in vivo programs for Wilson Disease (PM577) and AATD (PM647) towards IND/CTA submissions in 1H 2026 and mid-2026, respectively.
• Prime Editing technology is highlighted as a versatile and precise method for DNA modification without double-stranded breaks, potentially offering an improved safety and specificity profile.
• Preclinical data for PM577 (Wilson Disease) showed over 80% hepatocyte correction and restoration of copper homeostasis in animal models with no detectable off-target edits.
• Preclinical data for PM647 (AATD) demonstrated efficient correction of disease-causing mutations and restoration of wild-type M-AAT protein expression.
• The modularity of the Prime Editing platform is expected to enable efficient expansion into additional indications and streamline development processes, including potential umbrella regulatory strategies.
• Achieved major intellectual property milestones in 2025, including the issuance of two in-licensed U.S. patents, allowance of three additional in-licensed U.S. patent applications, and issuance/allowance of 15 ex-U.S. patents/applications.

Negatives

• The company has incurred significant operating losses since inception, with a net loss of $201.1 million in 2025 and an accumulated deficit of $888.4 million.
• Substantial doubt exists about the company's ability to continue as a going concern, as existing cash, cash equivalents, and investments are only sufficient to fund operations into 2027.
• The PM359 program for CGD, despite positive early clinical data, was strategically deprioritized in May 2025, indicating a shift away from a program that had shown human validation.
• The company is engaged in ongoing arbitration proceedings with Beam Therapeutics, which could result in monetary damages or the loss/transfer of its AATD program, a key pipeline asset.
• The company does not currently own any issued patents covering its Prime Editing technology or product candidates, relying heavily on in-licensed IP, which introduces dependency risks.
• Significant leadership changes occurred in 2025, with a new CEO, Executive Chair, and the departure of the former CEO and CSO.
• The company will need substantial additional funding beyond its current resources, and there is no assurance that capital will be available on acceptable terms or at all, potentially forcing delays or reductions in programs.

Risks

• Incurring significant losses for the foreseeable future and potentially never achieving or maintaining profitability.
• Existing cash, cash equivalents, and investments are not sufficient to fund operations for more than one year beyond the filing date, raising substantial doubt about the ability to continue as a going concern.
• Inability to raise substantial additional funding when needed, forcing delays, reductions, or elimination of research and product development programs or future commercialization efforts.
• Gene editing, including Prime Editing, is a relatively new technology not extensively clinically validated for human therapeutic use, and the approach is unproven and may never lead to marketable products.
• Clinical drug development is lengthy, expensive, and has an uncertain outcome, with unpredictable time and cost for regulatory approval, especially for novel gene editing products.
• Collaborations with third parties (e.g., Beam, BMS) may not be successful, or conflicts may arise, limiting the ability to capitalize on market potential or implement strategies, and potentially leading to loss of license rights.
• Inability to obtain and maintain sufficient patent and other intellectual property protection for Prime Editing technology and product candidates, or if the scope of protection is not broad enough, allowing third parties to commercialize similar products.
• Reliance on licenses from third parties (e.g., Broad Institute, Beam) means failure to comply with obligations could lead to loss of critical license rights.
• The intellectual property landscape around gene editing is highly dynamic, with potential for third parties to allege infringement, misappropriation, or other violations, leading to uncertain outcomes and interference with development efforts.
• Expected expansion of research, development, manufacturing, commercialization, and regulatory capabilities may lead to difficulties in managing growth and disrupt operations.
• Regulatory caution and ethical/legal concerns about gene therapy and genetic testing may result in additional regulations or restrictions, delaying or preventing development and commercialization.
• Difficulty enrolling patients in clinical trials due to rare disease populations, competition, or negative public perception of gene editing.
• Potential for product candidates, Prime Editing technology, or delivery modes (LNPs, AAVs, electroporation) to lack efficacy or cause serious adverse events, undesirable side effects, or unexpected characteristics, including off-target edits, immunogenicity, or liver toxicity.
• Significant competition from other gene editing, RNA-based, and gene replacement therapies, potentially leading to competitors achieving regulatory approval first or developing superior therapies.
• Adverse public perception of genetic therapies and gene editing, potentially impacting regulatory approval and/or demand for products.
• Market opportunities for product candidates may be smaller than anticipated, adversely affecting potential revenues.
• Clinical trial and product liability lawsuits could divert resources, incur substantial liabilities, and limit commercialization.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines, penalties, or significant costs.
• Gene editing therapies are complex to manufacture, with potential for production problems, supply chain delays, or difficulties in meeting regulatory standards.
• Inability to establish collaborations on a timely basis or on commercially reasonable terms, forcing the company to alter, reduce, or delay development and commercialization plans.
• Changes in patent law or their interpretation could diminish the value of patents, impairing the ability to protect Prime Editing technology and product candidates.
• Patent terms may be inadequate to protect competitive position for a sufficient amount of time, leading to competition from generics or biosimilars.
• Inability to protect the confidentiality of trade secrets, harming business and competitive position, especially with the use of AI technologies.
• Third parties may assert that employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets.
• Limited foreign intellectual property rights, potentially hindering protection and enforcement globally.
• Existing regulatory policies may change, and additional government regulations may be enacted, preventing, limiting, or delaying regulatory approval.
• Disruptions at the FDA, SEC, and other U.S. government agencies due to staffing, funding shortages, or global health concerns could hinder timely development, approval, or commercialization.
• Failure to comply with healthcare laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA) could result in substantial penalties.
• Healthcare and other reform legislation (e.g., ACA, IRA, OBBBA, GLOBE, GUARD, GENEROUS Models) may increase difficulty and cost of obtaining marketing approval and commercializing products, and affect pricing.
• Uncertainty regarding insurance coverage and reimbursement status of newly approved products, potentially limiting product revenues.
• Inability to obtain or realize benefits from expedited designations (e.g., fast track, breakthrough therapy, RMAT, designated platform technology, orphan drug).
• Employee misconduct or improper activities, including non-compliance with regulatory standards and insider trading.
• Risks related to health epidemics, pandemics, and other widespread outbreaks of contagious disease, disrupting operations.
• Vulnerability to interruption by disasters, terrorist activity, business disruptions, and other events beyond control.
• Increased attention to, and evolving expectations for, environmental, climate change, social, and governance (ESG) initiatives could increase costs, harm reputation, or adversely impact business.
• The increasing use of social media platforms presents risks and challenges, including noncompliance with regulations and reputational damage.
• Artificial intelligence presents risks and challenges, including security risks to confidential information, intellectual property, and personal data, and an uncertain regulatory environment.

Future Outlook

The company expects to incur significant expenses and increasing operating losses for the foreseeable future as it advances preclinical activities, initiates clinical trials for its Wilson Disease and AATD programs (IND/CTA filings planned for 1H 2026 and mid-2026, respectively), and continues platform development. It anticipates needing substantial additional funding beyond its current cash runway into 2027. The company aims to leverage its modular Prime Editing platform for efficient pipeline expansion and pursue disciplined portfolio prioritization. Discussions are underway with the FDA for a potential accelerated path to approval for PM359 for CGD. Initial clinical data for PM577 and PM647 are anticipated in 2027.

Management Comments

• "Our organization is intentionally structured to support clinical development and regulatory engagement as we prepare for multiple parallel clinical trials."
• "We believe Prime Editing represents the most versatile and precise method for rewriting, replacing, or repairing DNA sequences and may allow us to address a broad spectrum of diseases with an improved safety and specificity profile relative to earlier editing technologies."
• "We expect our focus on liver-directed in vivo editing, combined with the modularity of our platform, will allow us to build a pipeline with breadth and depth while maintaining operational efficiency and disciplined capital deployment."
• "Ultimately, our goal is to translate Prime Editing into a clinically and commercially validated therapeutic modality for the treatment across an array of severe genetic diseases and tissue types."
• "Discussions are underway with the FDA to explore a potential accelerated path to approval in the United States for PM359."
• "We believe that Prime Editing offers a potential best-in-class approach given the lack of bystander edits, off-target editing profile and ability for patients normal physiology to modulate AAT levels under native transcriptional control."
• "Management plans to provide for the Company’s capital requirements through financing or other transactions, and selling shares under the Company’s at the market offering program."

Industry Context

StockSavvy.ai notes that Prime Medicine operates in a highly competitive and rapidly evolving genetic medicines landscape, competing with established CRISPR nuclease companies (e.g., CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics), base editing firms (e.g., Beam, Verve Therapeutics), and other gene writing technologies (e.g., Tessera Therapeutics, Metagenomi). The company's focus on Prime Editing, which aims to avoid double-stranded breaks, positions it as a differentiated approach within this crowded field. The ongoing regulatory caution and evolving guidelines for gene therapies, as highlighted by FDA actions and the Loper Bright Enterprises v. Raimondo decision, create a challenging environment for all players. The BIOSECURE Act also introduces new geopolitical risks for supply chains, particularly for companies with China-based suppliers, which could impact the broader biopharmaceutical industry.

Comparison to Industry Standards

• Prime Editing's claim of avoiding double-stranded DNA breaks differentiates it from CRISPR nuclease systems (e.g., Cas9, Cas12a used by CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics) which are associated with indels and chromosomal rearrangements.
• Unlike base editors (e.g., Beam, Verve Therapeutics) which are limited to specific substitution types and may cause bystander edits, Prime Editing aims for broader editing outcomes (transversions, multi-base corrections, small insertions/deletions) without bystander activity.
• Prime Editing's permanent genomic changes contrast with transient RNA editing technologies (e.g., Ionis Pharmaceuticals, Alnylam Pharmaceuticals) that require repeated administration.
• The preclinical data for PM577 (Wilson Disease) showing >80% correction and normalization of copper distribution in humanized mouse models, with no detectable off-target edits, suggests a strong efficacy and safety profile compared to general industry benchmarks for early-stage gene editing therapies.
• The PM359 (CGD) Phase 1/2 clinical data demonstrating rapid and durable restoration of NADPH oxidase activity in treated patients provides early human validation for Prime Editing, a critical step in a field where few gene editing therapies have reached the market (only one approved in US/Europe).

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently engaged in arbitration proceedings with Beam Therapeutics Inc. regarding the Beam Collaboration Agreement. Beam filed an arbitration demand on April 16, 2025, alleging breach of the agreement by Prime Medicine for developing an AATD treatment and failing to transfer technical information. Beam seeks declaratory, injunctive, and monetary relief.
• Prime Medicine filed its own arbitration demand on April 18, 2025, seeking a declaration that its AATD program is within its defined field under the Beam Collaboration Agreement. The arbitrations have been consolidated and remain ongoing.
• An adverse resolution could result in monetary damages and/or an order to cease work on the AATD program and transfer it to Beam, materially affecting the company's competitive position and growth prospects.

Related Party Transactions

• In February 2024, Jeffrey Marrazzo (director) entered into an advisory services agreement, receiving an annual fee of $50,000 and an option to purchase 250,000 shares of common stock. This agreement expired in February 2025.
• In May 2025, Jeffrey Marrazzo (Executive Chair) entered into an executive chair agreement, receiving an annual fee of $100,000 and options to purchase 1,000,000 shares of common stock (time-based, performance-based, and market-based).
• Bristol-Myers Squibb Company (BMS) became a beneficial owner of more than 5% of voting securities in September 2024. The BMS Collaboration Agreement included a $55.0 million upfront payment and a $55.0 million equity investment from BMS.
• Entities affiliated with ARCH Venture Partners (Robert Nelsen, director) purchased 3,200,000 shares in the February 2024 public offering for $20,000,000 and 3,030,303 shares in the August 2025 public offering for $9,999,990.
• Entities affiliated with GV (David Schenkein, director) purchased 3,200,000 shares in the February 2024 public offering for $20,000,000 and 1,515,152 shares in the August 2025 public offering for $5,000,002.
• Newpath Partners, L.P. (Thomas Cahill, director affiliate) purchased 800,000 shares in the February 2024 public offering for $5,000,000.
• The Cystic Fibrosis Foundation (CFF) provided funding of up to $15.0 million in 2024 and an additional $24.0 million in 2025 for CF program development, including a $6.0 million cash funding and $6.0 million equity investment in 2025.
• The company paid $13.5 million to Myeloid Therapeutics in 2024 to resolve two arbitration proceedings related to a terminated collaboration agreement. Dr. Cahill is an affiliate of Newpath Partners, L.P. and holds more than 30% of Myeloid's voting securities.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future equity offerings due to the company's need for substantial additional funding. The 'going concern' doubt and increasing losses pose a direct threat to investment value. The ongoing arbitration with Beam Therapeutics could negatively impact the value of the AATD program and potentially lead to significant monetary damages or loss of the program.
• **Employees**: Workforce reductions in May 2025 impacted personnel expenses. The one-time option repricing in August 2025 aimed to incentivize and retain key talent, but overall stock price volatility could still affect employee morale and retention. Significant management changes may create uncertainty.
• **Customers/Patients**: The deprioritization of the PM359 CGD program, despite positive early data, could delay or alter access to a potentially curative treatment for CGD patients. Delays in clinical trials for Wilson Disease and AATD could postpone access to new therapies for patients with high unmet medical needs. The company's focus on precise, durable, and potentially curative treatments offers long-term hope for patients with genetic diseases.
• **Suppliers/Creditors**: The 'going concern' warning and need for additional financing could increase perceived credit risk, potentially affecting terms with suppliers and creditors. The BIOSECURE Act introduces new risks for suppliers, especially those with China-based operations, which could impact the company's supply chain.
• **Collaboration Partners (BMS, CFF)**: The BMS collaboration provides significant funding and validates the Prime Editing platform for ex vivo T-cell engineering. The CFF funding supports the CF program. However, the legal dispute with Beam Therapeutics could strain relationships with other partners or raise concerns about intellectual property enforceability and contractual clarity.

Next Steps

• Submit an IND/CTA for PM577 (Wilson Disease) in 1H 2026.
• Submit an IND/CTA for PM647 (AATD) in mid-2026.
• Obtain initial clinical data for PM577 in 2027, subject to regulatory clearance and trial execution.
• Obtain initial clinical data for PM647 in 2027.
• Continue regulatory interactions with the FDA to explore a potential accelerated path to approval for PM359 for CGD.
• Progress the Cystic Fibrosis program toward IND-enabling activities following preclinical proof-of-concept studies.
• Continue to evaluate collaborations that allow expansion of Prime Editing's reach and bolster financial resources.
• Invest in manufacturing, quality systems, and regulatory infrastructure to support advancement of multiple programs into clinical trials.
• Convert the New Registration Statement on Form S-3ASR to Form S-3 by post-effective amendments concurrently with the filing of this Annual Report on Form 10-K.

Key Dates

Recommendation

The explicit 'substantial doubt regarding our ability to continue as a going concern' is a critical red flag for any investor. Despite promising preclinical data and significant collaborations, the company's increasing net losses, high cash burn, and reliance on future, uncertain capital raises present an extremely high-risk profile. The ongoing legal dispute with Beam Therapeutics further jeopardizes a key pipeline asset. A seasoned investor would view the fundamental financial instability and operational risks as outweighing the long-term potential of its technology, making a 'sell' recommendation prudent to avoid further capital erosion.

Keywords

Prime Editing, Gene Editing, Biotechnology, Genetic Medicines, Wilson Disease, AATD, Cystic Fibrosis, CGD, SEC Filing, 10-K, Financial Results, Clinical Trials, Preclinical Development, Regulatory Approval, Intellectual Property, Collaborations, BMS, Beam Therapeutics, Cystic Fibrosis Foundation, Going Concern, Capital Raise, Biopharmaceutical, Rare Diseases, Orphan Drug, LNP Delivery, AAV Delivery, CAR T-cell, Oncology, Immunology, Liver Diseases, Lung Diseases, Hematologic Disorders